Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors
摘要:
A series of thiadiazole derivatives has been designed as potential allosteric, substrate competitive inhibitors of the protein kinase JNK. We report on the synthesis, characterization and evaluation of a series of compounds that resulted in the identification of potent and selective JNK inhibitors targeting its JIP-1 docking site. (C) 2009 Elsevier Ltd. All rights reserved.
Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors
摘要:
A series of thiadiazole derivatives has been designed as potential allosteric, substrate competitive inhibitors of the protein kinase JNK. We report on the synthesis, characterization and evaluation of a series of compounds that resulted in the identification of potent and selective JNK inhibitors targeting its JIP-1 docking site. (C) 2009 Elsevier Ltd. All rights reserved.
Synthesis of substituted 3-(5-amino-[1,3,4]thiadiazol-2-yl)-2<i>H</i>-pyrano[2,3-<i>c</i>]pyridin-2-ones
作者:Irina O. Zhuravel'、Sergiy M. Kovalenko、Alexandre V. Ivachtchenko、Valentin P. Chernykh、Pavlo E. Shinkarenko
DOI:10.1002/jhet.5570410407
日期:2004.7
An efficient two-step synthesis of novel 3-(5-amino-[1,3,4]thiadiazol-2-yl)-2H-pyrano[2,3-c]pyridine-2-ones was developed. In the first step, a new 2H-pyrano[2,3-c]pyridine-3-carboxamide 5 was prepared by Knoevenagel condensation of pyridoxal hydrochloride with cyanoacetamide. In the second step, the reaction of carboxamide 5 with a series of N4-substituted thiosemicarbazides yielded a library of 35
开发了有效的两步合成新型3-(5-氨基-[1,3,4]噻二唑-2-基)-2 H-吡喃并[2,3 - c ]吡啶-2-酮。第一步,通过吡pyr醛盐酸盐与氰基乙酰胺的Knoevenagel缩合制备新的2 H-吡喃并[2,3 - c ]吡啶-3-甲酰胺5。在第二步中,羧酰胺5与一系列N 4取代的硫代氨基脲的反应以高收率产生了35种离散化合物8 1-35}的库。讨论了导致这些产物的分子间再循环机理。
Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo)
申请人:Svensson Mats
公开号:US20070093483A1
公开(公告)日:2007-04-26
There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.